SOLICITATION NOTICE
68 -- Montanide ISA-51
- Notice Date
- 3/9/2004
- Notice Type
- Solicitation Notice
- NAICS
- 325412
—
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-40041-NG
- Response Due
- 3/24/2004
- Archive Date
- 4/8/2004
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
- Description
- The National Cancer Institute (NCI) Pharmaceutical Management Branch (PMB) plans to procure Montanide ISA-51 from the sole manufacturer, Seppic, Inc. Suite 225, 30 Two Bridges Road, Fairfield, New Jersey 02004. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13. The North American Industry Classification System code is 325412 and the business size standard is 500 employees. The Pharmaceutical Management Branch currently provides Montanide ISA-51 Sterile Injection, 3 ml ampules (NSC 675756) for twenty-four studies involving hundreds of study participants. This is an investigational agent that is not approved for commercial distribution in the United States. This agent is being studied as an adjuvant to other agents in various types of cancer. Montanide ISA (incomplete Seppic adjuvant)-51 Sterile Injection, 3 ml ampules (NSC 675756) is an experimental substance, which is intended to boost immune reactions to other experimental peptides. It is not commercially available in the United States. There are no generic equivalents, nor are there therapeutically equivalent agents that could be used in its place. The product should be delivered within 72 hours of ordering. The ampules must have a minimum expiration date of 18 months at the time of delivery to the NCI. A Certificate of Analysis (CoA) must be provided and all ampules must be from the same lot. Changing variables at this time will be detrimental to the experiment in progress. Period of Performance: The requirement will be an indefinite delivery, indefinite quantity (IDIQ) type contract for twelve (12) months only. FAR Clause 52.217-8 Option to Extend Service, (November 1999) applies. Seppic, Inc. is the only known source to the NCI that can provide the aforementioned substance. This substance is involved in patient care, therefore must remain consistent with ongoing treatment. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EST, on March 24, 2004. For further information please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@exchange.nih.gov or Caren Rasmussen at rasmussc@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/RCB/NCI-40041-NG/listing.html)
- Place of Performance
- Address: NCI/NIH
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN00540667-F 20040311/040309225734 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |